Free Trial
NASDAQ:AVTX

Avalo Therapeutics (AVTX) Stock Price, News & Analysis

Avalo Therapeutics logo
$4.78 -0.12 (-2.45%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.99 +0.21 (+4.29%)
As of 07/11/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Avalo Therapeutics Stock (NASDAQ:AVTX)

Key Stats

Today's Range
$4.61
$4.90
50-Day Range
$3.59
$5.02
52-Week Range
$3.39
$16.00
Volume
40,254 shs
Average Volume
64,423 shs
Market Capitalization
$51.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Buy

Company Overview

Avalo Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

AVTX MarketRank™: 

Avalo Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 450th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avalo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Avalo Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Avalo Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Avalo Therapeutics are expected to grow in the coming year, from ($19.07) to ($4.70) per share.

  • Price to Book Value per Share Ratio

    Avalo Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Avalo Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.38% of the float of Avalo Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Avalo Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avalo Therapeutics has recently increased by 41.77%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Avalo Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Avalo Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.38% of the float of Avalo Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Avalo Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avalo Therapeutics has recently increased by 41.77%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Avalo Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    Only 2 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.03% of the stock of Avalo Therapeutics is held by insiders.

  • Percentage Held by Institutions

    87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Avalo Therapeutics' insider trading history.
Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
See More Headlines

AVTX Stock Analysis - Frequently Asked Questions

Avalo Therapeutics' stock was trading at $7.43 at the beginning of 2025. Since then, AVTX shares have decreased by 35.7% and is now trading at $4.78.

Avalo Therapeutics, Inc. (NASDAQ:AVTX) posted its quarterly earnings results on Monday, May, 12th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.07) by $0.18.

Shares of Avalo Therapeutics reverse split on the morning of Friday, December 29th 2023.The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Sangamo Therapeutics (SGMO), FuelCell Energy (FCEL), Canoo (GOEV), Aurora Cannabis (ACB), Agenus (AGEN), Meta Platforms (META) and Geron (GERN).

Company Calendar

Last Earnings
5/12/2025
Today
7/13/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVTX
CIK
1534120
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$15.00
Potential Upside/Downside
+527.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.13 million
Net Margins
N/A
Pretax Margin
16,582.08%
Return on Equity
111.00%
Return on Assets
58.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.61
Quick Ratio
22.61

Sales & Book Value

Annual Sales
$440 thousand
Price / Sales
117.65
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.80 per share
Price / Book
0.37

Miscellaneous

Outstanding Shares
10,830,000
Free Float
10,500,000
Market Cap
$51.77 million
Optionable
Not Optionable
Beta
0.77
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:AVTX) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners